UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects

Cancer management and research, 2020-01, Vol.12, p.2731-2742

2020

Volltextzugriff (PDF)

Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer

International journal of molecular sciences, 2023-02, Vol.24 (4), p.4238

2023

Volltextzugriff (PDF)

Smoking is Not Associated with Lung Metastasis in Pancreatic Cancer

Cancer investigation, 2023-05, Vol.41 (5), p.487-490

2023

Volltextzugriff (PDF)

Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma

Frontiers in pharmacology, 2021-11, Vol.12, p.751568-751568

2021

Volltextzugriff (PDF)

Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

Hematology/oncology clinics of North America, 2017-04, Vol.31 (2), p.359-375

2017

Volltextzugriff (PDF)

Neoadjuvant Treatment for Pancreatic Cancer

Seminars in oncology, 2019-02, Vol.46 (1), p.19-27

2019

Volltextzugriff (PDF)

Advances in Systemic Therapy for Gastric Cancer

Gastrointestinal endoscopy clinics of North America, 2021-07, Vol.31 (3), p.607-623

2021

Volltextzugriff (PDF)

A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

Clinical cancer research, 2021-10, Vol.27 (20), p.5519-5527

2021

Volltextzugriff (PDF)

Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations

Journal of gastrointestinal oncology, 2015-10, Vol.6 (5), p.561-569

2015

Volltextzugriff (PDF)

Prolonged Response to HER2‐Directed Therapy in Three Patients with HER2‐Amplified Metastatic Carcinoma of the Biliary System: Case Study and Review of the Literature

The oncologist (Dayton, Ohio), 2021-08, Vol.26 (8), p.640-646

2021

Volltextzugriff (PDF)

A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX

The oncologist (Dayton, Ohio), 2024-04, Vol.29 (4), p.350-355

2024

Volltextzugriff (PDF)

Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab

Hematology reports, 2016-09, Vol.8 (3), p.6625-6625

2016

Volltextzugriff (PDF)

Targeting apoptotic pathways for cancer therapy

The Journal of clinical investigation, 2024-07, Vol.134 (14), p.1-12

2024

Volltextzugriff (PDF)

Immune checkpoint inhibitors for esophageal cancer: are we moving in the right direction?

Annals of translational medicine, 2019-07, Vol.7 (Suppl 3), p.S102-S102

2019

Volltextzugriff (PDF)

Adjuvant FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Pancreatic Cancer: A Brown University Oncology Research Group Phase II Study (BrUOG295)

American journal of clinical oncology, 2020-12, Vol.43 (12), p.857-860

2020

Volltextzugriff (PDF)

Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma

JAMA oncology, 2023-12, Vol.9 (12), p.1702

2023

Volltextzugriff (PDF)

Sustained Partial Response to Inhibition of the Mitogen-Activated Protein Kinase and Autophagy Pathways in Combination With Immune Checkpoint Blockade in KRAS -Mutated Adenocarcinoma of the Small Bowel

JCO precision oncology, 2020-11 (4), p.1122-1127

2020

Volltextzugriff (PDF)

Spontaneous Regression and Complete Response to Immune Checkpoint Blockade in a Case of High-Grade Neuroendocrine Carcinoma

JCO precision oncology, 2020-11 (4), p.1006-1011

2020

Volltextzugriff (PDF)

Oral administration of TRAIL-inducing small molecule ONC201/TIC10 prevents intestinal polyposis in the Apcmin/+ mouse model

American journal of cancer research, 2022-05, Vol.12 (5), p.2118-2131

2022

Volltextzugriff (PDF)

Abstract 1006: Combination therapy with MEK inhibitors and a novel anti-neoplastic drug, imipridone ONC212, demonstrates synergy in pancreatic ductal adenocarcinoma cell lines

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1006-1006

2021

Volltextzugriff (PDF)

CheMo4METPANC: A phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naïve pancreas adenocarcinoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS4200-TPS4200

2023

Volltextzugriff (PDF)

CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic treatment-naïve pancreatic adenocarcinoma

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.TPS4208-TPS4208

2024

Volltextzugriff (PDF)

Recurrence patterns and surveillance strategies in long-term survivors of resected pancreatic cancer

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e16361-e16361

2024

Volltextzugriff (PDF)

Variation in FOLFOX, FOLFIRI, and FOLFOXIRI effects on CD8+ T cell and PDL1 levels in MSS CRC patients

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3526-3526

2023

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(33)
Berichte
(2)

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Oncology
(13)
Pancreatic Cancer
(9)
Humans
(5)
Review
(4)
Health Aspects
(3)
Metastasis
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Biopsy
(2)
Brca Mutations
(2)
Cancer
(2)
Cancer Therapies
(2)
Carcinogen Exposure
(2)
Chemotherapy
(2)
Epidemiology
(2)
Gene Amplification
(2)
Genetic Aspects
(2)
Hematology
(2)
Immunotherapy
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects

Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer

Smoking is Not Associated with Lung Metastasis in Pancreatic Cancer

Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma

Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

Neoadjuvant Treatment for Pancreatic Cancer

Advances in Systemic Therapy for Gastric Cancer

A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations

Prolonged Response to HER2‐Directed Therapy in Three Patients with HER2‐Amplified Metastatic Carcinoma of the Biliary System: Case Study and Review of the Literature

A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX

Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab

Targeting apoptotic pathways for cancer therapy

Immune checkpoint inhibitors for esophageal cancer: are we moving in the right direction?

Adjuvant FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Pancreatic Cancer: A Brown University Oncology Research Group Phase II Study (BrUOG295)

Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma

Sustained Partial Response to Inhibition of the Mitogen-Activated Protein Kinase and Autophagy Pathways in Combination With Immune Checkpoint Blockade in KRAS -Mutated Adenocarcinoma of the Small Bowel

Spontaneous Regression and Complete Response to Immune Checkpoint Blockade in a Case of High-Grade Neuroendocrine Carcinoma

Oral administration of TRAIL-inducing small molecule ONC201/TIC10 prevents intestinal polyposis in the Apcmin/+ mouse model

Abstract 1006: Combination therapy with MEK inhibitors and a novel anti-neoplastic drug, imipridone ONC212, demonstrates synergy in pancreatic ductal adenocarcinoma cell lines

CheMo4METPANC: A phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naïve pancreas adenocarcinoma

CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic treatment-naïve pancreatic adenocarcinoma

Recurrence patterns and surveillance strategies in long-term survivors of resected pancreatic cancer

Variation in FOLFOX, FOLFIRI, and FOLFOXIRI effects on CD8+ T cell and PDL1 levels in MSS CRC patients

Suchergebnisse filtern